Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has coverage initiated with a Buy rating

ME Staff
-
0

Analyst Ratings For Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)

Today, Citigroup initiated coverage on Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) with a Buy.

There are 6 Buy Ratings, 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) is Buy with a consensus target price of $17.0833 per share, a potential 10.72% upside.

Some recent analyst ratings include

  • 9/13/2018-Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has coverage initiated with a Buy rating
  • 9/5/2018-Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) had its Buy rating reiterated by Cowen
  • 8/15/2018-Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) gets upgraded to Buy by HC Wainwright with a price target of $21.00
  • 8/13/2018-Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) had its Hold rating reiterated by Chardan Capital with a $14.50 price target
  • 4/20/2018-Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) had its Outperform rating reiterated by Evercore ISI with a $17.00 price target

Recent Insider Trading Activity For Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has insider ownership of 19.85% and institutional ownership of 87.02%.

  • On 9/5/2018 James B Weissman, Insider, sold 2,301 with an average share price of $17.50 per share and the total transaction amounting to $40,267.50.
  • On 8/15/2018 Dennis Langer, Director, sold 14,531 with an average share price of $16.00 per share and the total transaction amounting to $232,496.00.
  • On 5/9/2018 James B Weissman, Insider, sold 10,000 with an average share price of $15.00 per share and the total transaction amounting to $150,000.00.
  • On 4/20/2018 James B Weissman, Insider, sold 8,965 with an average share price of $13.00 per share and the total transaction amounting to $116,545.00.
  • On 3/19/2018 James B Weissman, Insider, sold 1,035 with an average share price of $13.00 per share and the total transaction amounting to $13,455.00.
  • On 12/18/2017 Bain Capital Life Sciences Inv, Director, bought 285,000 with an average share price of $7.00 per share and the total transaction amounting to $1,995,000.00.
  • On 11/16/2016 Dennis Langer, Director, sold 23,766 with an average share price of $3.52 per share and the total transaction amounting to $83,656.32.

About Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia. The company has a collaborative research and license agreement with Boehringer Ingelheim International GmbH; a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd.; and a license agreement with City of Hope. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Recent Trading Activity for Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)
Shares of Dicerna Pharmaceuticals Inc closed the previous trading session at 15,43 −0,72 4,46 % with 16.48 shares trading hands.